Kimberly-Clark formally requested antitrust approval from the European Commission for its $40 billion acquisition of Kenvue. The target company manufactures household brands including Tylenol and Listerine. This filing follows the initial deal announcement in November 2025.
European regulators set a provisional decision deadline for September 29. The merger aims to create a consumer health leader with $32 billion in combined annual revenue.
Shareholders have already approved the transaction. The deal is expected to close in the second half of 2026, pending final regulatory clearances.